- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- Study: Daily aspirin use may reduce risk of ovarian cancer by 20%
- ROUNDTABLE: Pharmacy’s future in sync with technology
- CVS Caremark to stop selling tobacco in all store locations
- Q&A: Genetic profiling with Dr. Anita Goel of Nanobiosym
INDIANAPOLIS — A drug made by Eli Lilly prevented the most common form of lung cancer from progressing in elderly patients when added to chemotherapy, according to results of a late-stage clinical trial.
Lilly released results of the 939-patient phase-3 "PARAMOUNT" study, which found that maintenance therapy with the injected drug Alimta (pemetrexed), added to the chemotherapy drug cisplatin, reduced the risk of disease progression in patients ages 70 years and older with advanced nonsquamous no-small cell lung cancer, or NSCLC.
In the study, patients were given Alimta or a placebo. Among the 92 patients ages 70 years and older, Alimta reduced the risk of disease progression by 65% compared with placebo. Among those younger than 70 years, the drug reduced disease progression by 31%.
Results from the analysis were presented at the 2011 European Multidisciplinary Cancer Congress in Stockholm.